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Abstract
Although only limited long-term studies evaluating thermal ablation of renal masses have been performed, it appears that thermal 
ablation has a comparable 5-year success rate to that of partial or total nephrectomy. This technique is often used in patients who 
are not good candidates for partial or total nephrectomy. Contrast-enhanced ultrasound (CEUS) has been recently approved by 
the Food and Drug Administration for characterization of focal liver lesions in adults and pediatric patients. CEUS can be used 
off  label for renal applications and has been used for years in Europe and Asia. It has several advantages over  contrast-enhanced 
computed tomography for use as the technique to guide and evaluate efficacy of thermal ablation of renal masses. These include 
the ability to visualize small amounts of enhancement, repeat dosing to evaluate efficacy of an ablation during a procedure, thin 
slice thickness, and real-time visualization. Ultrasound contrast is also non-nephrotoxic and non-hepatotoxic, allowing evalua-
tion of patients with renal insufficiency. This article reviews the use of CEUS for the guidance and follow-up of thermal ablative 
procedures of renal masses.
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Introduction
According to the American Cancer Society, in the United 
States, 63,340 new cases of renal cancer will occur in 2018, 
an incidence that has been increasing since the 1990s and has 
only recently begun to level off  (1). Much of this increase 
has been attributed to the improved diagnosis of small renal 
masses (SRM) that are localized to the kidney and often 
 incidentally found in asymptomatic patients being imaged 
for other reasons (1). The most common type of renal cancer 
found is renal cell carcinoma (RCC), which accounts for 9 
out of every 10 cases and makes up 3% of all adult neoplasms 
(1, 2). When examining cases of RCC, Bhan et al. (3) found 
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that 48–66% of these tumors can be attributed to these in-
cidentally discovered SRM. Atri et al. (2) further state that 
the greatest increase in RCC diagnosis has been early stage 
T1 tumors, which they define as SRM when the tumor is less 
than 4 cm in axial diameter, and has an observed 5-year sur-
vival rate of 81%. Stages II and III tumors have an observed 
survival rate of 74% and 53%, respectively, while the survival 
rate for stage IV tumors is as low as 8% (1). It is important 
to note, however, that these data include patients with RCC 
who may have died of other causes. With this relatively recent 
rise in incidence, along with the ever-advancing technology in 
the medical field, treatment of these renal cancers, especially 
RCC, has become a frequently discussed topic.
The long time tried and true method for treating RCC is 
surgical resection, which carries a low mortality and high suc-
cess rate (1). For this reason, it should remain the standard 
of care for patients with potentially curable RCC. With that 
being said, a significant number of patients who have renal 
cancer are not favorable surgical candidates. There are a va-
riety of reasons that may make a patient ineligible for partial 
nephrectomy or surgical resection. These include significant 
comorbidities, a life expectancy between 1 and 10 years, 
chronic renal failure, patient only having one or a transplant 
kidney, advanced age, bilateral RCC, Von Hippel–Lindau 
(VHL) disease, or refusal of conventional therapy (4–6). 
Many of these contraindications can be commonly found in 
the elderly, which is problematic since the average age of di-
agnosis of RCC is 64 (1, 7). Chronic renal failure is especially 
important because those requiring dialysis also have an in-
creased risk of developing RCC (1). Radiofrequency ablation 
(RFA) or other forms of thermal ablation are possible alter-
native treatments for many of these patients.
Though RFA is a relatively new treatment for renal tumors 
and long-term efficacy remains to be seen, the initial data sug-
gest that not only is it safe and well tolerated by patients, but 
also has a comparable 5-year success rate to that of partial 
or total nephrectomy (4, 5, 8). One of its biggest benefits is 
that the procedure is renal sparing, and RFA is currently used 
for small tumors, usually less than 5 cm, in patients who are 
not candidates for surgical removal (7). Besides being used 
as an attempted cure of RCC, it may also be used to treat 
RCC-associated intractable hematuria, local recurrences, 
isolated metastases, and palliation of symptoms (6). RFA is 
considered a minimally invasive procedure in which a probe 
is inserted into the target tissue and alternating electrical 
currents are used to generate heat to destroy tumor cells and 
associated neovascularity. This procedure is guided by ad-
vanced imaging techniques that help position the probe and 
are paramount in evaluating the success of ablation (9). Tra-
ditionally, computed tomography (CT) is used in the initial 
pre-ablation evaluation, as well as to guide the probe place-
ment, evaluate the ablation zone, and tumor post-ablation. 
Ultrasound (US) has also been used in combination with CT 
or alone because of its ability to provide a real-time image. 
Both these techniques, however, have some limitations in the 
form of contrast-related problems (e.g., renal insufficiency), 
lack of live image in CT, and reduced visualization and accu-
racy in US. One possible alternative to guide the RFA pro-
cedure is to use contrast-enhanced ultrasound (CEUS), an 
advanced technique that utilizes ultrasound contrast agents 
(UCAs) to improve lesion visualization in difficult cases and 
to either immediately or at a later time detect residual tumor 
after ablation (4, 10).
Ultrasound Contrast Agents
UCAs are gas-containing microspheres with an outer shell of 
lipid, protein or polymer (11). With a diameter ranging from 
1 to 10 µm, these microbubbles are roughly the size of a red 
blood cell. This size allows them to pass through capillaries 
and be delivered to any tissue that maintains circulation, all 
the while avoiding extravascular passage (8, 11, 12). With no 
extravascular passage, UCAs are considered to be pure blood 
pool agents that are neither filtered nor excreted by the renal 
system (4). However, the most important property of these 
agents is that the microspheres will resonate when exposed 
to frequencies that are commonly used in diagnostic ultra-
sonography (8, 9, 11). The resulting reflection and scatter 
from the resonating microspheres leads to increased echoge-
nicity, allowing for real-time imaging of the microcirculation. 
The microspheres will last for about 5–7 min inside the blood 
vessels until they dissolve (11). The internal gas is then ex-
haled by the lungs while the shell is metabolized by the body.
In practice, UCAs possess a low incidence of side effects 
and are considered safe for patients, especially those with de-
creased renal function (4, 10, 12, 13). These patients benefit 
from the fact that UCAs are not excreted into the urine and 
therefore not nephrotoxic, a contradistinction to the agents 
used for CT and magnetic resonance imaging (MRI). They 
also have a very low rate, less than 0.002%, of anaphylactoid 
reactions, which is lower than that of CT contrast agents (10, 
11). A previous reaction to CT contrast agents also does not 
preclude one from UCAs because the two agents are com-
pletely different. Currently, the Food and Drug Administra-
tion (FDA) (14) has approved the intravenous use of several 
UCAs for use in echocardiography, as well as one agent for 
use in hepatic imaging. However, many physicians around the 
world have found success utilizing this technique for imaging 
a variety of tissues, including renal tumors (10).
CEUS of Renal Masses
Currently, complex renal cysts are evaluated using CT and 
classified by an interpretation standard, such as the Bosniak 
Classification System. This system ranges from I to IV, with 
category I having qualities of a simple cyst and category IV 
that of a clearly malignant tumor (12, 15). Category IIF is 
composed of more complex cystic lesions that need to be 
CEUS-guided radiofrequency ablation
Journal of Kidney Cancer and VHL 2018; 5(1): 7–14 9
followed up because they cannot be classified as category II. 
Category III is reserved for those indeterminate cystic renal 
masses that are neither definitively benign nor malignant. 
These categories are then used to make decisions on whether 
surgical versus conservative management is best for the pa-
tient. In practice, however, there exists inter-reader variation 
in making distinction between categories II, IF, and III le-
sions, which poses potential problems in making these rec-
ommendations (12). It is with these types of tumors that 
CEUS has a significant advantage over CT.
The microspheres utilized in CEUS allow for real-time 
imaging of renal masses with improved depiction of renal 
vessels, solid tumor vascularity, and detection of septal and 
peripheral wall vascularity of complex renal masses (11, 
12, 16). Enhancement with UCAs usually lasts for 5–7 min 
(11). The first to enhance is the arterial pedicle and the main 
branches, followed by the renal cortex a few seconds later (10, 
11). With signals independent of the angle of insonation, the 
microspheres even provide adequate depiction of renal pole 
perfusions, something lacking in Doppler US (10). The next 
to follow is medullary perfusion, with the outer medulla en-
hancing before the gradually filling pyramids (10, 11). Many 
experts have also noticed that patients with chronic renal 
disease have less intense enhancement that fades earlier. As 
previously stated, CEUS is safe in these patients, unlike CT 
contrast, because it is not excreted into the urine and there-
fore not nephrotoxic. Historically, a common alternative to 
CT with contrast for patients with chronic renal disease is 
MRI with contrast. However, unlike MRI, CEUS can be used 
in patients with arthroprosthesis or pacemakers, and faces 
less of a problem of movement artifacts from patients who 
cannot stay still (9). Furthermore, there has been mounting 
concern about the use of gadolinium MRI contrast agents in 
patients with chronic renal failure and how it may be associ-
ated with nephrogenic systemic sclerosis (6, 9).
When using CEUS, a renal tumor is best depicted during 
the arterial phase, usually beginning about 15–20 s after con-
trast injection (9, 12). Meloni et al. (9) stated that during this 
phase, the hypervascularity of renal tumors will appear with 
brighter intensity than the surrounding normal renal par-
enchyma. They also noted that tumors had faster washout, 
leading to a hypoechoic appearance 30–40 s after contrast 
injection. Quaia et al. (12) and other researchers were able to 
use these characteristics-enhancing patterns in order to create 
vascularity profiles that can be used to determine the likeli-
hood of a tumor being benign or malignant, similar to how 
the Bosniak classifications are used for CT (17). With regard 
to accuracy, several studies have shown CEUS to have com-
parable to improved results versus CT in the discovery and 
evaluation of complex renal cysts (5, 9, 12, 18). Quaia et al. 
(12) did note, however, that inter-reader agreement improved 
with increasing experience, indicating that one must consider 
the learning curve of using CEUS. With such encouraging re-
sults, less contraindications and cheaper cost versus CT and 
MRI, CEUS may not only become increasingly utilized in 
the evaluation and follow-up of complex renal cysts, but can 
also be applied to interventions such as RFA.
CEUS-Guided RFA
Apart from initial tumor evaluation, CEUS has also shown 
promise in the localization, guidance and postoperative im-
aging with regard to RFA. RFA has found an increasing role 
in the treatment of small renal tumors in patients who are 
not candidates for surgical resection, as previously outlined 
in the Introduction (19). It is an outpatient procedure in 
which a probe is inserted into the tumor and delivers thermal 
energy within the tissue that is created via a high-frequency 
alternating current released from the active electrode at the 
tip (1,  7,  20). According to Boss et al. (7), the subsequent 
thermal damage will lead to coagulative necrosis and cellular 
death once the target temperature exceeds 48–50°C. The size 
of this area of necrosis is linearly dependent on treatment 
time and exponentially dependent on the temperature and 
can be predicted using biophysical relationships (7). How-
ever, the tissue destruction around the applicator tip limits 
the achievable ablation size by decreasing the energy depo-
sition through increased electrical impedance. With this in 
mind, it is suggested for larger tumors (>2 cm) to use either 
multiple probes simultaneously or a single probe repositioned 
after each ablation to ensure complete destruction (4, 7, 9).
Traditionally, the RFA probes are placed under CT guid-
ance. CT provides excellent visibility of the probe, but takes 
multiple steps of image capture and probe adjustment be-
cause it does not provide a live image (1, 8). In comparison, 
recent studies have shown that with its continuous image and 
vascular characterization, CEUS can allow for improved 
orientation and guidance of the probe into the target tumor 
(1, 10, 11). CEUS may then be used to evaluate the target 
zone after waiting for 5–10 min post-ablation to allow for 
the heat-generated gas to dissipate (10, 11). This helps elim-
inate artifact in the post-procedure image when evaluating 
the ablation zone. Ablation success is characterized as non- 
enhancement in the area of the previously enhancing lesion, 
while residual tumor will appear as a crescent-like enhancing 
region within the ablation zone (4, 9–11, 13). However, these 
post-treatment imaging results should be closely compared 
with pre-treatment imaging results so that one does not mis-
interpret larger blood vessels surrounding the region as resid-
ual tumor (10, 11, 13). Such timely postoperative imaging is 
not always possible when using CT because of the nephro-
toxicity limitations associated with CT contrast agents. Fur-
thermore, if  residual tumor exists, it would take a separate 
procedure on a later date to fully treat (4, 5, 7). When using 
CEUS, this same residual tumor can be recognized shortly 
after the first ablation and targeted by repositioning the 
probe because US contrast can be safely administered multi-
ple times per session.
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With the probability of tumor recurrence after RFA to be es-
timated as high as 12.9% at 24 months, posttreatment follow-up 
imaging is critical (3). This is especially true when considering 
the findings of Sanchez (5) that most incomplete treatments 
using RFA are detected within the first 3 months. Traditionally, 
follow-up imaging for post-RFA of renal tumors utilizes either 
CT or MRI. However, there have been several recent studies 
showing the efficacy of CEUS in follow-up and how it is a repro-
ducible technique that may be performed early in the follow-up 
because it carries no renal toxicity (6). Kong et al. (4) performed 
RFA on 63 patients with 64 RCCs and compared the results 
of CEUS with CT at 1-month follow-up imaging. They found 
that the concordance between the two modalities for detecting 
residual vascular enhancement was 100%, with CEUS having 
a sensitivity of 100% and a specificity of 96.6%. These findings 
are similar to those referenced in European Federation of So-
cieties for Ultrasound in Medicine and Biology (EFSUMB) 
Guidelines and Recommendations on the Clinical Practice of 
Contrast Enhanced Ultrasound (10), which state that CEUS 
studies provided similar overall accuracy to that of CT/MRI 
in confirming the accuracy of treatment. Kong et al. (4) also 
noted that CEUS exhibits higher concordance with the defin-
itive necrosis area than conventional US. The fact that CEUS 
has higher concordance with the area of necrosis is confirmed in 
the study of Johnson et al. (8) where they performed post-RFA 
imaging immediately after ablation and at 1 week on several pig 
kidneys and then compared the imaging data to the gross RFA 
lesions after dissection. However, not all studies have been as 
favorable to the use of CEUS over the traditional methods of 
CT/MRI.
A study by Hoeffel et al. (6) compared the results of CEUS 
with that of CT/MRI for 43 patients (66 renal tumors) post-
RFA at 24 h and 6 weeks while using CT/MRI at 1 year as a 
reference standard. The study found that all imaging modalities 
were more accurate at 6 weeks than at 24 h and that CEUS had 
high specificity and predictive values for residual tumor detec-
tion (6). However, CEUS had lower sensitivity than that of CT/
MRI, and had worse image quality at the upper renal poles and 
at the periphery of the treated areas. Hoeffel et al. also noted that 
CEUS performed better in the assessment of hypervascular tu-
mors, a concept that has been noted in several other studies and 
could be related to the ability of UCAs to image the microvascu-
lature (6, 9, 12). Other limitations of CEUS may include lesion 
location as well as the specific properties of UCAs when used 
in the kidneys. The intensity of the reflected echoes decreased 
significantly with depth, which means that deep lesions, or those 
in obese patients, may appear to have reduced vasculature (11). 
Bowel gas interposition may also interfere with the quality of 
CEUS evaluation, but Meloni et al. (9) stated that these limita-
tions can be reduced with an imaging approach that minimizes 
depth and gas interference, as well as newer contrast-specific 
modes such as contrast pulse sequence imaging. CEUS has the 
advantage of no renal excretion so that the dense contrast in the 
collecting system does not mask an abnormality (11).
CEUS Guidelines
The following outlines our standard procedure for RFA of 
renal masses under CEUS guidance:
(1) First a patient must be determined to be a candidate for 
RFA based on the pre-procedure imaging of the renal 
mass. Tumor size, position and stage, as well as other 
patient factors are used to determine candidacy. If  the 
patient is a candidate, informed consent is obtained, 
and a pre-procedure physical examination and labora-
tory studies including standard coagulation profile are 
obtained.
(2) Either on the day of or a few days before the procedure, a 
pre-ablation CEUS is performed to evaluate the size and 
vascular supply of the tumor. These images can be used 
to plan the puncture site and needle trajectory, and will 
also be compared to the post-ablation images to deter-
mine success.
(3) Prior to the procedure, most patients will undergo 
 conscious sedation, although general anesthesia may 
be required depending on certain patient factors and 
wishes. Once the patient is prepped and ready, the 
RFA needle is positioned within the mass using image 
 guidance. Depending on the size or shape of the tumor, 
 multiple probes may be placed before beginning ablation. 
Ablation is then performed for about 10–15 min depend-
ing on tumor size.
(4) After waiting 5 to 10 min for the heat-generated gas to 
dissipate, a repeat CEUS is performed to look for resid-
ual tumor. These images are compared closely to the 
pre-ablation CEUS images and if  any residual tumor 
is detected, the RFA needle is repositioned for a repeat 
ablation. Once no residual tumor is viewed on post- 
ablation CEUS, the RFA probe is retracted slowly, while 
turned on, to ablate the track and reduce the risk of 
tumor seeding.
(5) Most studies follow a schedule of follow-up imaging 
every 3 months in the first year and every 6 months in 
the second year. Some choose to stagger CEUS and CT 
follow-up imaging over the first year, while others per-
form both at every follow-up. The first year is the most 
important because that is when most residual tumors are 
detected.
Case Studies of CEUS RFA
The following case studies provide an overview of how to 
perform CEUS for guidance of RFA for renal tumors.
Figure 1 demonstrates the steps in performing a 
CEUS  RFA. Figure 1A is the unenhanced B-mode US 
before the procedure. In this case, the mass is easily iden-
tified. If  the mass is not visualized well, a CEUS can be per-
formed to confirm the size and location of  the mass. Figure 
1B shows the position of  the RFA needle in the mass. 
CEUS-guided radiofrequency ablation
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Figure 1C is the image after the injection of  the ultra-
sound  contrast confirming the position of  the needle in 
the  mass. Figure 1D shows that there is no flow remain-
ing in the renal mass, confirming complete ablation of  the 
lesion.
Figure 2 demonstrates that after the first ablation, a second 
dose of ultrasound contrast can be performed to evaluate for 
residual tumor. The CEUS contrast lasts for about 5 min. 
During the RFA, gas bubbles are generated and appear as 
CEUS contrast when imaging. Waiting for about 5 min after 
the completion of the ablation will eliminate this problem. 
If  bubbles still remain in real-time CEUS imaging, the bub-
bles generated from the procedure will not move whereas the 
UCA bubbles in residual tumor will be visualized as moving. 
In this case, a large area of residual tumor (arrows) remains. 
The CEUS image can be used to reposition the RFA needle 
into the residual tumor.
CEUS can be used to follow patients for residual or re-
current tumor with high accuracy. Any residual tumor will 
be identified as areas of increased enhancement. Absence of 
blood flow as in Figure 3B confirms complete ablation of the 
renal tumor. Note that it is not possible to determine if  con-
trast is not utilized in Figure 3A. Figure 4 demonstrates a 
case where residual tumor (calipers) is present.
Occasionally a complete ablation cannot be obtained. This 
is often from significant blood flow to the mass or the mass 
adjacent to the collection system which acts as heat sinks and 
does not allow for adequate temperature to ablate the tumor. 
Figure 5 demonstrates a renal mass on the B-mode image 
(A) and the CEUS image (B). Immediately post-RFA, the 
B-mode (C) and CEUS (D) demonstrate minimal ablation 
of the tumor.
Figure 6 demonstrates the advantage of CEUS over CT. 
Because CEUS has a contrast-only image, small amounts of 
enhancement are easily identified. On CT (as well as MRI) 
there is signal from the associated soft tissues, making it diffi-
cult to identify small amounts of enhancement.
Conclusion
Lately, there has been an increase in the use of  CEUS to 
guide RFA of renal tumors. Using CEUS instead of  CT as 
guidance has the advantages of  providing a real-time image, 
being safe in patients with chronic renal disease, and being 
able to provide an immediate post-ablation image. When 
performing follow-up imaging to screen for residual tumor, 
CEUS yielded results similar to that of  CT and MRI and 
has the advantage of  a contrast-only image allowing for 
visualization of  small amounts of  enhancement. If  studies 
continue to look favorably on CEUS as an alternative for 
evaluating and guiding the treatment of  renal tumors, it 
may become an FDA-approved contrast method for RFA 
of renal tumors and provide a unique alternative to other 
imaging modalities.
Figure 1. Images demonstrating RFA of an RCC. (A) B-mode image of the RCC (calipers) pre-procedure, (B) B-mode image 
demonstrating positioning of the RFA needle (arrow) in the RCC, (C) image after injection of ultrasound contrast confirming 
the needle (arrow on low MI B-mode image on right) within the tumor, and (D) CEUS post-procedure demonstrating complete 
ablation of the RCC (arrow, right).
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Figure 4. Tumor recurrence/inadequate ablation. Patient presented for CEUS examination 6 weeks after RFA. (A) The B-mode 
image demonstrates a complex mass (arrow) with solid and cystic components. It is not possible to determine if  there is residual 
tumor. (B) CEUS image demonstrates the tumor (calipers) with residual flow in the posterior part of the tumor (arrow).
BA
Figure 3. Successful ablation. Patient presented for 3-month post-RFA evaluation. (A) B-mode image before the ablation. Large 
heterogeneous tumor is noted on gray scale examination (arrow). (B) Absence of residual blood flow (arrow) is demonstrated on 
CEUS examination.
Figure 2. Multiple doses of ultrasound contrast can be administered during the RFA procedure. The contrast agents last for about 
5 min so that residual enhancement is not present on additional doses. In this case, a CEUS study was performed after the first 
ablation. Note that there is residual tumor (arrows). The RFA needle can then be repositioned into the residual tumor for addi-
tional ablation. This confirms that the tumor is completely ablated at the first setting. The similar process cannot be performed 
in CT because only one dose of CT contrast can be administered.
CEUS-guided radiofrequency ablation
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Figure 5. Failed ablation. Patient has history of prior left nephrectomy for RCC and presented with right renal mass. (A) Gray 
scale image of mass (arrow) pre-ablation. (B) CEUS demonstrating increased flow in tumor (arrow) at inferior pole of right 
kidney. (C) Gray scale image post-RFA of the mass (arrow). (D) CEUS post-RFA demonstrating flow throughout the tumor 
(arrow), indicating failed RFA.
Figure 6. Images 6 months post-RFA of an RCC. (A) CT scan without contrast in this patient with renal failure. The ablated 
RCC (arrows) has significant attenuation making it difficult to determine if  there is residual tumor. Even if  contrast is adminis-
tered, the background tissue makes it difficult to identify small areas of enhancement. (B) CEUS scan at the same 6-month post-
RFA time point as the CT in (A). Ultrasound contrast agents can be used in patients with renal failure. Note that the excellent 
tissue suppression of CEUS allows for a contrast-only image, making it easy to see that there is no enhancement and no residual 
or recurrent tumor.
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